Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Howlader

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Medical Care|April 13, 2026
Response to Letter to the Editor: Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (SEER) Treatment Data Use Agreement: A Review of Published StudiesYoon Duk Hong, Angela B Mariotto, Denise R Lewis, et al.
Journal of the National Cancer Institute|June 15, 2011
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomesArnold L Potosky, Jennifer L Malin, Benjamin Kim, et al.
Medical Care|September 22, 2025
Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (SEER) Treatment Data Use Agreement: A Review of Published StudiesYoon Duk Hong, Angela B Mariotto, Denise R Lewis, et al.
The Journal of Urology|August 12, 2005
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trialRuth D Etzioni, Nadia Howlader, Pamela A Shaw, et al.
Journal of the National Cancer Institute. Monographs|November 24, 2014
Cancer survival: an overview of measures, uses, and interpretationAngela B Mariotto, Anne-Michelle Noone, Nadia Howlader, et al.
Journal of the National Cancer Institute|September 24, 2024
Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 declineNadia Howlader, Huann-Sheng Chen, Anne-Michelle Noone, et al.
JAMA Network Open|March 6, 2020
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked DatabaseLucia C Petito, Xabier García-Albéniz, Roger W Logan, et al.
Journal of the National Cancer Institute|April 30, 2014
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 statusNadia Howlader, Sean F Altekruse, Christopher I Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2019
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer PatientsAllison W Kurian, Kevin C Ward, Nadia Howlader, et al.
Blood|April 30, 2008
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsDana E Rollison, Nadia Howlader, Martyn T Smith, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Medical Care|April 13, 2026
Response to Letter to the Editor: Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (SEER) Treatment Data Use Agreement: A Review of Published StudiesYoon Duk Hong, Angela B Mariotto, Denise R Lewis, et al.
Journal of the National Cancer Institute|June 15, 2011
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomesArnold L Potosky, Jennifer L Malin, Benjamin Kim, et al.
Medical Care|September 22, 2025
Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (SEER) Treatment Data Use Agreement: A Review of Published StudiesYoon Duk Hong, Angela B Mariotto, Denise R Lewis, et al.
The Journal of Urology|August 12, 2005
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trialRuth D Etzioni, Nadia Howlader, Pamela A Shaw, et al.
Journal of the National Cancer Institute. Monographs|November 24, 2014
Cancer survival: an overview of measures, uses, and interpretationAngela B Mariotto, Anne-Michelle Noone, Nadia Howlader, et al.
Journal of the National Cancer Institute|September 24, 2024
Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 declineNadia Howlader, Huann-Sheng Chen, Anne-Michelle Noone, et al.
JAMA Network Open|March 6, 2020
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked DatabaseLucia C Petito, Xabier García-Albéniz, Roger W Logan, et al.
Journal of the National Cancer Institute|April 30, 2014
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 statusNadia Howlader, Sean F Altekruse, Christopher I Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2019
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer PatientsAllison W Kurian, Kevin C Ward, Nadia Howlader, et al.
Blood|April 30, 2008
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsDana E Rollison, Nadia Howlader, Martyn T Smith, et al.
Pageof 5